|Bid||2.75 x 500|
|Ask||3.05 x 2000|
|Day's range||2.73 - 2.86|
|52-week range||2.24 - 4.60|
|PE ratio (TTM)||1.79|
|Earnings date||6 Nov 2017 - 10 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.75|
Ophthotech Corporation announced today that the first patient has been enrolled in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura® , complement C5 inhibitor, in patients with autosomal recessive Stargardt disease .
Ophthotech Corporation announced today the election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to its Board of Directors, effective immediately.
Ophthotech Corporation announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 36th Annual J.P.
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Ophthotech Corporation breached their fiduciary duties to shareholders.
Regeneron (REGN) announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for Eylea with an action date of Aug 11, 2018.
Ophthotech (OPHT) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex (VRTX) received CHMP recommendation for label expansion of Orkambi in children aged 6 to 11 years with CF who have two copies of the F508del mutation.
Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.
On a per-share basis, the New York-based company said it had profit of $5.25. The clinical-stage biotech focused on eye diseases posted revenue of $206.7 million in the period. The company's shares closed ...
Ophthotech Corporation today announced financial and operating results for the third quarter ended September 30, 2017 and provided a business update.